左旋门冬氨酸鸟苷酸联用复方甘草酸苷治疗肝硬化肝性脑病的探讨

To evaluate the efficacy of L-ornithine-L-aspartate (Hepa-Merz) with stronger neo-minophagen C (SNMC) for treatment of hepatic encephalogpahty of liver cirrhosis.80 patients with hepatic encephalopathy of liver cirrhosis were devided into two groups: group A were treated by intravenous infusion of L-ornithine-L-aspartate (Hepa-Merz) and SNMC;group B wered treated by intravenous infusion of sodium glutamate and SNMC, total course of treatment were 7 days.The levels of serum ammonia, ALT, AST and total bilirubin were detected before and after treatment.Serum ammonia in group A and group B whose before treatment and after treatment were 76.5±26.5 ummol/L vs 36.28±11.51 ummol/L and 71.58±16.99 ummol/L vs 49.8±16.46 ummol/L, (P<0.05) ;whereas the serum total bilirubin in group A and group B whose before and after were 40.05±15.12 ummol/L vs 20.95±11.27 ummol/L (P<0.001) and 38.95±14.9 ummol/L vs 22.33±10.9ummol/L (P<0.001) respectively.No serious side effects were found during the treatment.The combination of L-ornithine-L-aspartate (Hepa-Merz) with SNMC is a safe and effective treatment for hepatic encephalopathy of liver cirrhosis;besides, it decrease the level of serum ammonia and total bilirubin significantly.